mynth
02/2014100%LBO

Nemera acquired by Montagu Private Equity

FRANCE Life Sciences / Medical Devices / Medical Consumables EV €500M–1.5bn

Context

The deal involves the carve-out of Rexam's healthcare devices and prescription retail divisions, which will be acquired by Montagu Private Equity. The transaction is subject to regulatory approval and is expected to be completed in the coming weeks. The strategic rationale behind the deal is to create a standalone company that can focus on the healthcare sector and leverage Montagu Private Equity's expertise and resources to drive growth and expansion. The deal is expected to enhance the competitiveness of the company and improve its market position, while also providing opportunities for innovation and investment in new products and technologies. The company's management team will work closely with Montagu Private Equity to develop a growth strategy that builds on the company's strengths and addresses the evolving needs of the healthcare market. With a strong foundation in place, the company is well-positioned to capitalize on emerging trends and opportunities in the healthcare sector, including the growing demand for innovative medical devices and pharmaceutical packaging solutions.

Nemera, which reported an EBITDA margin of [members only] in 2013, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2013
€250–500M
€50–100M
[members only]
2012
€250–500M
€50–100M
[members only]

Other operations with Nemera

Other operations with Nemera
DateAcquirerTargetCountrySector
08/2025LGT CAPITAL PARTNERSNEMERAFRANCEMedical Consumables
10/2018ASTORGNEMERAFRANCEMedical Consumables

Other operations with Montagu Private Equity

Other operations with Montagu Private Equity
DateAcquirerTargetCountrySector
12/2025MONTAGU PRIVATE EQUITY / KOHLBERGTELEFLEX MEDICAL OEMUNITED STATESMedical Consumables
06/2025MONTAGU PRIVATE EQUITYMULTIFONDSLUXEMBOURGFinancial Services / Banking
05/2023TA ASSOCIATES / MONTAGU PRIVATE EQUITYHARVESTFRANCEFinancial Services / Banking
02/2022MONTAGU PRIVATE EQUITY / PARTNERS GROUPHTL BIOTECHNOLOGYFRANCECDMO
07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCEImplants & Prosthetics
01/2021MONTAGU PRIVATE EQUITYIMV TECHNOLOGIESFRANCER&D Biotech
03/2020TETHYS INVEST / CPPIB (CANADA PENSION PLAN INVESTMENT BOARD) / MONTAGU PRIVATE EQUITYGALILEO GLOBAL EDUCATIONFRANCEEducation Providers
06/2017HG CAPITAL / GIC / MONTAGU PRIVATE EQUITY / ICGVISMA GROUPNORWAYERP, HR & Finance
03/2014MONTAGU PRIVATE EQUITYARKOPHARMAFRANCENutrition & Dietary Supplements
06/2009MONTAGU PRIVATE EQUITYADB SAFEGATEBELGIUMAerospace, Naval & Defense

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
09/2014INSTITUT MERIEUX / SAGARD / SOFIPROTEOLCEVA SANTE ANIMALEFRANCEAnimal Health
03/2014MONTAGU PRIVATE EQUITYARKOPHARMAFRANCENutrition & Dietary Supplements
01/2014FIVE ARROWSDUTSCHERFRANCEMedical Consumables
10/2013ARDIANLABORATOIRES ANIOSFRANCEMedical Consumables
07/2013CHARTERHOUSEDOC GENERICIITALYGenerics / Labs
06/2013BC PARTNERSANTELLIQFRANCEAnimal Health
06/2013EURAZEOPÉTERS SURGICALFRANCEMedical Consumables
01/2013ELITECH GROUPVITAL DIAGNOSTICSUNITED STATESDiagnostic Equipment
08/2012BC PARTNERSAENOVA GROUPGERMANYCDMO
05/2011AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIALAGARRIGUEFRANCEImplants & Prosthetics

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €250–500M

EBITDA range: €50–100M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nemera by Montagu Private Equity are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: nemera

FAQ

What transaction does this page cover?

This page covers Montagu Private Equity’s acquisition of 100% of Nemera, a French company specialised in Medical Devices, in 2014, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with Astorg in October 2018 (see the dedicated deal page for details).

How was the acquisition of Nemera by Montagu Private Equity valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Nemera’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Nemera generated annual revenue estimated in the €250–500M range and EBITDA in the €50–100M bracket (FY 2013). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.